MDR-TB in children is a globally emerging problem. Current regimens are long, toxic and typically require long hospital admission. Data on the optimal use of 2nd line drugs and novel treatment strategies are urgently needed for children. This symposium aims to address practical aspects of the management of children and adolescents with DR-TB from geographically diverse settings. Emerging data on the pharmacokinetics and safety of existing 2ndline drugs and novel TB drugs will be shared. Qualitative data on children’s experience of MDR-TB treatment will be presented.

**Target audience**

Intended target audience: NTP personnel, paediatric TB care providers, clinical researchers, regulatory, funders and pharma.

**Objectives**

1. To provide evidence on management and treatment outcomes in paediatric-MDR-TB from diverse settings
2. To provide new evidence on the optimal use of existing 2ndline TB drugs in children with MDR-TB
3. To share early experiences in the clinical evaluation of novel TB drugs in children with MDR-TB
4. To provide data on the psychosocial impact of MDR-TB in children

**Keywords**

MDR-TB; children; adolescents; treatment; drugs; PK, safety; novel; evaluation; psychosocial

**Coordinator(s)**

Anneke Hesseling (South Africa), James Seddon (UK)

**Chair(s)**

**Presentations**

09:15 - 09:30 Patient and caregiver perspectives of MDR-TB treatment in children

09:35 - 09:50 Treatment outcomes in children with paediatric MDR-TB in Georgia

09:55 - 10:10 Experiences in treating children with MDR-TB in India

10:15 - 10:35 Emerging data on the pharmacokinetics and safety of secondline line TB drugs in children: Moxifloxacin vs. Ofloxacin and Amikacin

10:40 - 10:55 Early experiences in the evaluation of a novel TB drug in children

11:00 - 11:15 Discussion